Cargando…

Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)

OBJECTIVE: Current studies of newborn screening for Fabry disease in Taiwan have revealed a remarkably high prevalence of cardiac-type Fabry disease with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A). DESIGN: Retrospective cohort study. SETTING: Tertiary medical centre. PARTICIPANTS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Hsiang-Yu, Liu, Hao-Chuan, Huang, Yu-Hsiu, Liao, Hsuan-Chieh, Hsu, Ting-Rong, Shen, Chia-I, Li, Shao-Tzu, Li, Cheng-Fang, Lee, Li-Hong, Lee, Pi-Chang, Huang, Chun-Kai, Chiang, Chuan-Chi, Lin, Ching-Yuang, Lin, Shuan-Pei, Niu, Dau-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717460/
https://www.ncbi.nlm.nih.gov/pubmed/23864212
http://dx.doi.org/10.1136/bmjopen-2013-003146
_version_ 1782277695951863808
author Lin, Hsiang-Yu
Liu, Hao-Chuan
Huang, Yu-Hsiu
Liao, Hsuan-Chieh
Hsu, Ting-Rong
Shen, Chia-I
Li, Shao-Tzu
Li, Cheng-Fang
Lee, Li-Hong
Lee, Pi-Chang
Huang, Chun-Kai
Chiang, Chuan-Chi
Lin, Ching-Yuang
Lin, Shuan-Pei
Niu, Dau-Ming
author_facet Lin, Hsiang-Yu
Liu, Hao-Chuan
Huang, Yu-Hsiu
Liao, Hsuan-Chieh
Hsu, Ting-Rong
Shen, Chia-I
Li, Shao-Tzu
Li, Cheng-Fang
Lee, Li-Hong
Lee, Pi-Chang
Huang, Chun-Kai
Chiang, Chuan-Chi
Lin, Ching-Yuang
Lin, Shuan-Pei
Niu, Dau-Ming
author_sort Lin, Hsiang-Yu
collection PubMed
description OBJECTIVE: Current studies of newborn screening for Fabry disease in Taiwan have revealed a remarkably high prevalence of cardiac-type Fabry disease with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A). DESIGN: Retrospective cohort study. SETTING: Tertiary medical centre. PARTICIPANTS: 21 patients with cardiac-type Fabry disease (15 men and 6 women) as well as 15 patients with classic Fabry disease (4 men and 11 women) treated with biweekly intravenous infusions of agalsidase β (1 mg/kg) or agalsidase α (0.2 mg/kg) for at least 6 months. OUTCOME MEASURES: These data were collected at the time before enzyme replacement therapy (ERT) began and followed up after ERT for at least 6 months, including patient demographics, medical history, parameter changes of cardiac status and renal functions, plasma globotriaosylsphingosine (lyso-Gb3) and Mainz Severity Score Index. RESULTS: After 6–39 months of ERT, plasma lyso-Gb3 was found to be reduced in 89% (17/19) and 93% (14/15) of patients with cardiac-type and classic Fabry disease, respectively, which indicated an improvement of disease severity. For patients with cardiac-type Fabry disease, echocardiography revealed the reduction or stabilisation of left ventricular mass index (LVMI), the thicknesses of intraventricular septum (IVS) and left posterior wall (LPW) in 83% (15/18), 83% (15/18) and 67% (12/18) of patients, respectively, as well as 77% (10/13), 73% (11/15) and 60% (9/15) for those with classic type. Most patients showed stable renal function after ERT. There were statistically significant improvements (p<0.05) between the data at baseline and those after ERT for values of plasma lyso-Gb3, LVMI, IVS, LPW and Mainz Severity Score Index. No severe clinical events were reported during the treatment. CONCLUSIONS: ERT is beneficial and appears to be safe for Taiwanese patients with cardiac-type Fabry disease, as well as for those with the classic type.
format Online
Article
Text
id pubmed-3717460
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-37174602013-07-22 Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A) Lin, Hsiang-Yu Liu, Hao-Chuan Huang, Yu-Hsiu Liao, Hsuan-Chieh Hsu, Ting-Rong Shen, Chia-I Li, Shao-Tzu Li, Cheng-Fang Lee, Li-Hong Lee, Pi-Chang Huang, Chun-Kai Chiang, Chuan-Chi Lin, Ching-Yuang Lin, Shuan-Pei Niu, Dau-Ming BMJ Open Pharmacology and Therapeutics OBJECTIVE: Current studies of newborn screening for Fabry disease in Taiwan have revealed a remarkably high prevalence of cardiac-type Fabry disease with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A). DESIGN: Retrospective cohort study. SETTING: Tertiary medical centre. PARTICIPANTS: 21 patients with cardiac-type Fabry disease (15 men and 6 women) as well as 15 patients with classic Fabry disease (4 men and 11 women) treated with biweekly intravenous infusions of agalsidase β (1 mg/kg) or agalsidase α (0.2 mg/kg) for at least 6 months. OUTCOME MEASURES: These data were collected at the time before enzyme replacement therapy (ERT) began and followed up after ERT for at least 6 months, including patient demographics, medical history, parameter changes of cardiac status and renal functions, plasma globotriaosylsphingosine (lyso-Gb3) and Mainz Severity Score Index. RESULTS: After 6–39 months of ERT, plasma lyso-Gb3 was found to be reduced in 89% (17/19) and 93% (14/15) of patients with cardiac-type and classic Fabry disease, respectively, which indicated an improvement of disease severity. For patients with cardiac-type Fabry disease, echocardiography revealed the reduction or stabilisation of left ventricular mass index (LVMI), the thicknesses of intraventricular septum (IVS) and left posterior wall (LPW) in 83% (15/18), 83% (15/18) and 67% (12/18) of patients, respectively, as well as 77% (10/13), 73% (11/15) and 60% (9/15) for those with classic type. Most patients showed stable renal function after ERT. There were statistically significant improvements (p<0.05) between the data at baseline and those after ERT for values of plasma lyso-Gb3, LVMI, IVS, LPW and Mainz Severity Score Index. No severe clinical events were reported during the treatment. CONCLUSIONS: ERT is beneficial and appears to be safe for Taiwanese patients with cardiac-type Fabry disease, as well as for those with the classic type. BMJ Publishing Group 2013-07-16 /pmc/articles/PMC3717460/ /pubmed/23864212 http://dx.doi.org/10.1136/bmjopen-2013-003146 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Pharmacology and Therapeutics
Lin, Hsiang-Yu
Liu, Hao-Chuan
Huang, Yu-Hsiu
Liao, Hsuan-Chieh
Hsu, Ting-Rong
Shen, Chia-I
Li, Shao-Tzu
Li, Cheng-Fang
Lee, Li-Hong
Lee, Pi-Chang
Huang, Chun-Kai
Chiang, Chuan-Chi
Lin, Ching-Yuang
Lin, Shuan-Pei
Niu, Dau-Ming
Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)
title Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)
title_full Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)
title_fullStr Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)
title_full_unstemmed Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)
title_short Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)
title_sort effects of enzyme replacement therapy for cardiac-type fabry patients with a chinese hotspot late-onset fabry mutation (ivs4+919g>a)
topic Pharmacology and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717460/
https://www.ncbi.nlm.nih.gov/pubmed/23864212
http://dx.doi.org/10.1136/bmjopen-2013-003146
work_keys_str_mv AT linhsiangyu effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga
AT liuhaochuan effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga
AT huangyuhsiu effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga
AT liaohsuanchieh effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga
AT hsutingrong effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga
AT shenchiai effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga
AT lishaotzu effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga
AT lichengfang effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga
AT leelihong effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga
AT leepichang effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga
AT huangchunkai effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga
AT chiangchuanchi effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga
AT linchingyuang effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga
AT linshuanpei effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga
AT niudauming effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga